The company "Julfaar - Al Khaleej for Pharmaceutical Industries" announced a reduction in the accumulated losses to the end of 2024 to 305 million dirhams, which constitutes 26.4% of its capital.
The taken and planned measures to eliminate the accumulated losses include increasing the company's sales in strategic markets, restructuring the product portfolio, launching new products in various therapeutic areas in diverse markets, as well as additional funding.
The reason for this accumulation, the company noted, is the transfer of accumulated losses from previous years, noting that the losses decreased by 41.7 million dirhams in 2024 due to the total income for the past year.
